Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90018 | 0.89 | ALOX15 (0.53) | P2RY12ALOX15NCF1ALDH1A1 | |
| SCHEMBL3332342 | 0.84 | P2RY12 (0.53) | P2RY12ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL20515870 | 0.80 | ALOX15 (0.69) | P2RY12ALOX15NCF1ALDH1A1 | |
| SCHEMBL31389238 | 0.80 | ALOX15 (0.57) | P2RY12ALOX15SMN1; SMN2 | |
| SCHEMBL30438659 | 0.80 | ALOX15 (0.69) | P2RY12ALOX15NCF1ALDH1A1 | |
| SCHEMBL3328186 | 0.78 | CASP3 (0.48) | P2RY12ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL13131925 | 0.78 | CDC25B (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6889759 | 0.78 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30002312 | 0.77 | SMN1; SMN2 (0.54) | ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL1733527 | 0.77 | SMN1; SMN2 (0.54) | ALOX15ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | P2RY12 4561/4885ALOX15 3459/4885NCF1 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.